Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Bridgepoint Group plc is a leading British private investment company specializing in private equity, infrastructure, credit, and private wealth strategies within the mid-market segment. Founded in 1985 as NatWest Equity Partners and headquartered at 5 Marble Arch in London, United Kingdom, it manages over $86 billion in assets under management across eight investment strategies and 15 offices worldwide, including New York, Paris, and Singapore. The firm targets middle-market, lower mid-market, small mid-cap, and small-cap companies, focusing on growth capital, buyouts, direct lending, and syndicate debt in sectors such as advanced industrials, automation, agricultural sciences, energy transition enablers, business services, financial services, professional services, consumer products, digital brands, video games, wellbeing, healthcare, pharmaceuticals, and Med-Tech. Bridgepoint Group plc invests primarily in the United Kingdom, New York, and Nordic regions, with equity commitments ranging from £4.77 million to £125 million and enterprise values up to €1,000 million. Notable past investments include Virgin Active, Pret a Manger, and Deliveroo, underscoring its role in fostering growth for specialized businesses globally.
£2.93
+£0.12 (+4.35%)
EOD Jul 3, 2026
Operating margin is thin at 7.04%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 22.6%, still solid. Margins contracted 14.1pp, which offsets some of the top-line progress.
At 60x earnings, the current multiple leaves limited room for execution misses or growth deceleration. Operating margin contracted 14.1pp YoY, cost discipline may be slipping.
59.8x earnings, 23.4x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
£476M
▲ +22.6% YoY
Net Income (TTM)
£57M
▼ -17.9% YoY
Op. Margin
7.04%
▼ -14.1pp YoY
ROIC
0.56%
▼ -2.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
£104M
▲ +1211.4% YoY
Op. Cash Flow (TTM)
£187M
▲ +166.1% YoY
Net Debt
£145M
Cash & Equiv.
£3.10B
3Y CAGR: +21.5%
3Y CAGR: +109.3%
Continue Research
At a P/E of 59.8 and a price-to-free-cash-flow of 23.4, Bridgepoint Group (BPT.XLON) trades below a two-stage DCF intrinsic value of about £6.15 per share, so at £2.93 the stock looks undervalued (110.0% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Bridgepoint Group scores 56/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 3.8%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about £6.15 per share for BPT.XLON, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around £4.61. At today's £2.93, that puts the stock about 110.0% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Bridgepoint Group scores 56 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 7.0% operating margin and a 0.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Bridgepoint Group pays a regular dividend of about £0.11 per share per year (typically in quarterly installments), a yield of roughly 3.8% at the current price. That is a payout ratio of about 161.7% of earnings, so the dividend is stretched at this level. Bridgepoint Group has grown the dividend at roughly 32.2% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For BPT.XLON's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. BPT.XLON currently trades below its estimated intrinsic value and scores 56/100 on quality (mixed). It also yields about 3.8%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.